TargetRx Atlas

MRNA basic information

  • mRNA ID:ENST00000261769
  • Gene Name:CDH1 (E-cadherin)
  • mRNA database:Ensembl
  • mRNA expression :up-regulated
  • mRNA Method:RT-PCR
  • mRNA Pathway:EMT signalin pathway
  • Evidence:validated
  • (mRNA-drug)

Drug basic information

  • Drug ID:DB11544
  • Drug Name:Salinomycin
  • Drug Method:up regulated the gene expression

Disease basic infommation

  • Disease:colorectal cancer
  • Tissue:cell lines (HT29,SW480)

Other information

  • Title:Salinomycin selectively targets ＇CD133+＇ cell subpopulations and decreases malignant traits in colorectal cancer lines
  • Journal:Ann Surg Oncol
  • Published:2011
  • PubMed ID:21267784
  • Abstract:Background:Cancer stem-like cells (CSCs) in colorectal cancers (CRC) may account for the failure of treatments because they are resistant to many current anticancer therapies. Salinomycin, a potassium ionophore, was recently identified as a selective inhibitor of breast CSCs. Methods:The human CRC cell lines HT29 and SW480 were treated with salinomycin and oxaliplatin. Cell viability was determined with cell counting kit 8. Fraction of CD133+ cell subpopulations was assessed by Flow Cytometric analysis. Clonogenecity and migration were determined with soft agar and Boyden chamber assays. Molecular changes were assessed by immunofluorescence staining, RT-PCR, and Western blot analysis. Results:We report that salinomycin reduces the proportion of CD133+ subpopulations in human CRC HT29 and SW480 cells. Furthermore, salinomycin treatment decreases colony-forming ability and cell motility in HT29 cells. Moreover, salinomycin downregulates the expression of vimentin and induces the E-cadherin expression in HT29 cells. Conclusions:This study demonstrates the ability of salinomycin to selectively target "CD133+" cell subpopulations and decrease the malignant traits in colorectal cancer lines.
@Copyright Harbin Medical University
　The 2nd Affiliated Hospital of Harbin Medical University
　 备案号：鲁ICP备2022025566号-3